Opportunities Preloader

Please Wait.....

Report

Active Pharmaceutical Ingredient Market by Type (Innovative, Generic), Manufacturer (Captive, Merchant), Synthesis (Synthetic, Biotech), Product (mAb, Hormones, Cytokines), Drug (OTC,Rx) Application (Diabetes, Oncology, CVD) - Global Forecast to 2027

Market Report I 2022-12-02 I 361 Pages I MarketsandMarkets

The global Active Pharmaceutical Ingredient (APIs) market is estimated to reach USD 145.9 billion by 2022 to USD 216.4 billion in 2027, at a CAGR of 8.2% during the forecast period. Factors such as the increasing uptake of biopharmaceuticals, the growing importance of generics, and the rising focus on precision medicine are some of the major factors driving the growth of the global APIs market.

"The biotech APIs segment is expected to grow at the highest CAGR during the forecast period."

On the basis of the type of synthesis, the APIs market is categorized into synthetic APIs and biotech APIs. In 2021, the synthetic APIs segment accounted for the largest share. However, the biotech APIs segment is expected to grow at a higher rate over the forecast period. Factors such as the growing demand for biotech drugs due to their specificity in action and advancements in biotechnology are driving market growth in the market.

"The monoclonal antibodies segment is expected to account for the largest share of the global biotech APIs market."

Based on product, the biotech APIs market is segmented into monoclonal antibodies, hormones & growth factors, cytokines, fusion proteins, therapeutic enzymes, recombinant vaccines, and blood factors. In 2021, the monoclonal antibodies segment was estimated to account for the largest share of the biotech APIs market.

"North America to dominate the market during the forecast period."

In 2021, North America dominated the market, followed by Europe. The major factors driving the overall growth of the APIs market in this region include the presence of major pharmaceutical and biopharmaceutical manufacturing facilities, an increasing government focus on generic drugs, rising demand for biologics and specialty drugs, and technological advancements in the manufacturing processes of APIs. This market segment is expected to grow at a modest rate due to a combination of economic and healthcare severity measures as well as the introduction of low-cost and generic versions of branded drugs.

Breakdown of the profile of primary participants:
- By Company Type: Tier 1 - 37%, Tier 2 - 22%, and Tier 3 - 41%
- By Designation: C-level Executives - 25%, Directors - 20%, Others - 55%
- By Region: North America - 40%, Europe - 27%, Asia Pacific - 20%, and RoW - 13%
List of companies profiled in the report
- Pfizer, Inc. (US),
- Novartis AG (Switzerland),
- Sanofi (France),
- Boehringer Ingelheim (Germany),
- Bristol-Myers Squibb (US),
- Teva Pharmaceutical Industries Ltd. (Israel),
- Eli Lilly and Company (US),
- GlaxoSmithKline plc (UK),
- Merck & Co., Inc. (US),
- AbbVie Inc. (US),
- F. Hoffmann-La Roche Ltd. (Switzerland),
- AstraZeneca (UK),
- Cipla, Inc. (India),
- Mylan N.V. (US),
- Dr. Reddy's Laboratories Ltd. (India),
- Sun Pharmaceutical Industries Ltd. (India),
- API Pharma Tech (India),
- BDR Pharmaceuticals Internationals Pvt. Ltd. (India),
- Sreepathi Pharmaceuticals Limited (India),
- Shilpa Medicare Limited (India),
- Evonik Industries AG (Germany),
- Aurobindo Pharma Limited (India).
Research Coverage:
This report provides a picture of the global APIs market. It aims at estimating the size and future growth potential of the market across different segments, such as type, potency, type of synthesis, type of drug, therapeutic application, and region. Furthermore, the report also includes an in-depth competitive analysis of key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall APIs market and its subsegments. Also, this report will help stakeholders to better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. It will also enable stakeholders to understand the pulse of the market and provide them with information on key market drivers, restraints, challenges, and opportunities.

1 INTRODUCTION 48
1.1 STUDY OBJECTIVES 48
1.2 MARKET DEFINITION 48
1.2.1 INCLUSIONS AND EXCLUSIONS 48
1.3 MARKET SCOPE 49
1.3.1 MARKETS COVERED 49
FIGURE 1 MARKET SEGMENTATION 49
1.3.2 GEOGRAPHIC SCOPE 49
1.3.3 YEARS CONSIDERED 50
1.4 CURRENCY 50
1.5 LIMITATIONS 50
1.6 STAKEHOLDERS 50
1.7 SUMMARY OF CHANGES 51
2 RESEARCH METHODOLOGY 52
2.1 RESEARCH DATA 52
FIGURE 2 RESEARCH DESIGN 52
2.1.1 SECONDARY DATA 53
2.1.1.1 Key data from secondary sources 53
2.1.2 PRIMARY DATA 54
2.1.2.1 Primary sources 54
2.1.2.2 Key data from primary sources 55
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS 55
2.2 MARKET SIZE ESTIMATION 56
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 56
FIGURE 5 MARKET SIZE ESTIMATION: DEMAND-SIDE ANALYSIS 56
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 58
FIGURE 6 DATA TRIANGULATION METHODOLOGY 58
2.4 MARKET SHARE ESTIMATION 59
2.5 ASSUMPTIONS 59
3 EXECUTIVE SUMMARY 60
FIGURE 7 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2022 VS. 2027 (USD BILLION) 60
FIGURE 8 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE, BY TYPE OF SYNTHESIS, 2021 61
FIGURE 9 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2022 VS. 2027 (USD BILLION) 61
FIGURE 10 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2022 VS. 2027 (USD BILLION) 62
FIGURE 11 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE, BY THERAPEUTIC APPLICATION, 2021 62
FIGURE 12 GEOGRAPHICAL SNAPSHOT OF ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 63
4 PREMIUM INSIGHTS 65
4.1 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET OVERVIEW 65
FIGURE 13 INCREASING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET 65
4.2 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE AND COUNTRY (2021) 66
FIGURE 14 INNOVATIVE APIS SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2021 66
4.3 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 67
FIGURE 15 ASIA PACIFIC TO WITNESS HIGHEST GROWTH IN FORECAST PERIOD 67
5 MARKET OVERVIEW 68
5.1 INTRODUCTION 68
5.2 MARKET DYNAMICS 68
FIGURE 16 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 68
5.2.1 DRIVERS 68
5.2.1.1 Pharmaceutical and biopharmaceutical capacity expansion 68
5.2.1.2 Growing importance of generics 69
TABLE 1 INDICATIVE LIST OF DRUGS GOING GENERIC IN 2021 70
5.2.1.3 Increasing uptake of biopharmaceuticals 70
TABLE 2 US: INDICATIVE LIST OF BIOLOGICS THAT GAINED REGULATORY APPROVAL IN 2021 71
5.2.1.4 Technological advancements in API manufacturing 71
5.2.1.5 Focus on precision medicine 72
5.2.1.6 Increasing incidence of chronic diseases 73
5.2.2 RESTRAINTS 74
5.2.2.1 Complications during API manufacturing 74
5.2.2.2 Low profit margins and high manufacturing costs 74
5.2.3 OPPORTUNITIES 74
5.2.3.1 Emerging biosimilars market 74
TABLE 3 US: INDICATIVE LIST OF BIOSIMILARS THAT GAINED REGULATORY APPROVAL (2021-2022) 75
5.2.3.2 Highly potent active pharmaceutical ingredients 75
5.2.3.3 Emerging markets 75
5.2.3.4 Emerging technologies/processes 76
5.2.4 CHALLENGES 76
5.2.4.1 Increasing penetration of counterfeit drugs 76
5.3 VALUE CHAIN ANALYSIS 77
FIGURE 17 MAJOR VALUE ADDED DURING MANUFACTURING 77
5.4 SUPPLY CHAIN ANALYSIS 78
FIGURE 18 DIRECT DISTRIBUTION-STRATEGY PREFERRED BY PROMINENT COMPANIES 78
5.5 ECOSYSTEM ANALYSIS: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 79
FIGURE 19 ECOSYSTEM ANALYSIS OF ACTIVE PHARMACEUTICAL INGREDIENTS MARKET 79
5.6 PATENT ANALYSIS 80
FIGURE 20 PATENT APPLICATIONS FOR ACTIVE PHARMACEUTICAL INGREDIENTS, JANUARY 2010-DECEMBER 2021 80
5.7 KEY CONFERENCES AND EVENTS 81
TABLE 4 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS, 2022-2023 81
5.8 TARIFF AND REGULATORY LANDSCAPE 82
5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82
TABLE 5 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82
TABLE 6 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82
TABLE 7 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82
5.9 PORTER'S FIVE FORCES ANALYSIS 83
TABLE 8 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: PORTER'S FIVE FORCES ANALYSIS 83
5.9.1 THREAT OF NEW ENTRANTS 83
5.9.2 THREAT OF SUBSTITUTES 83
5.9.3 BARGAINING POWER OF SUPPLIERS 83
5.9.4 BARGAINING POWER OF BUYERS 83
5.9.5 INTENSITY OF COMPETITIVE RIVALRY 83
5.10 KEY STAKEHOLDERS AND BUYING CRITERIA 84
5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS 84
FIGURE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF ACTIVE PHARMACEUTICAL INGREDIENTS 84
5.10.2 BUYING CRITERIA FOR ACTIVE PHARMACEUTICAL INGREDIENTS 84
FIGURE 22 KEY BUYING CRITERIA FOR END USERS 84
5.11 PRICING ANALYSIS 85
TABLE 9 IMPORTERS FOR ANTIBIOTICS (HS CODE - 2941) 85
TABLE 10 EXPORTERS FOR ANTIBIOTICS (HS CODE - 2941) 86
TABLE 11 IMPORTERS FOR NUCLEIC ACIDS AND THEIR SALTS, WHETHER OR NOT CHEMICALLY DEFINED; HETEROCYCLIC COMPOUNDS (EXCLUDING WITH OXYGEN ONLY OR WITH NITROGEN HETERO-ATOM[S] ONLY (HS CODE - 2934) 87
TABLE 12 EXPORTERS FOR NUCLEIC ACIDS AND THEIR SALTS, WHETHER OR NOT CHEMICALLY DEFINED; HETEROCYCLIC COMPOUNDS (EXCLUDING WITH OXYGEN ONLY OR WITH NITROGEN HETERO-ATOM[S] ONLY (HS CODE - 2934) 88
TABLE 13 IMPORTERS FOR HORMONES, PROSTAGLANDINS, THROMBOXANES, AND LEUKOTRIENES, NATURAL OR REPRODUCED BY SYNTHESIS; DERIVATIVES AND STRUCTURAL ANALOGUES THEREOF INCLUDE CHAIN-MODIFIED POLYPEPTIDES, USED PRIMARILY AS HORMONES (HS CODE - 2937) 89
TABLE 14 EXPORTERS FOR HORMONES, PROSTAGLANDINS, THROMBOXANES AND LEUKOTRIENES, NATURAL OR REPRODUCED BY SYNTHESIS; DERIVATIVES AND STRUCTURAL ANALOGUES THEREOF INCLUDE CHAIN-MODIFIED POLYPEPTIDES, USED PRIMARILY AS HORMONES (HS CODE - 2937) 90
5.12 TRADE ANALYSIS 91
TABLE 15 TOP 10 IMPORTERS FOR ANTIBIOTICS (HS CODE - 2941) 91
TABLE 16 TOP 10 EXPORTERS OF ANTIBIOTICS (HS CODE - 2941) 91
TABLE 17 TOP 10 IMPORTERS OF NUCLEIC ACIDS AND THEIR SALTS, WHETHER OR NOT CHEMICALLY DEFINED; HETEROCYCLIC COMPOUNDS (EXCLUDING WITH OXYGEN ONLY OR WITH NITROGEN HETERO-ATOM[S] ONLY (HS CODE - 2934) 92
TABLE 18 TOP 10 EXPORTERS OF NUCLEIC ACIDS AND THEIR SALTS, WHETHER OR NOT CHEMICALLY DEFINED; HETEROCYCLIC COMPOUNDS (EXCLUDING WITH OXYGEN ONLY OR WITH NITROGEN HETERO-ATOM[S] ONLY (HS CODE - 2934) 92
TABLE 19 TOP 10 IMPORTERS OF HORMONES, PROSTAGLANDINS, THROMBOXANES AND LEUKOTRIENES, NATURAL OR REPRODUCED BY SYNTHESIS; DERIVATIVES AND STRUCTURAL ANALOGUES THEREOF INCLUDE CHAIN-MODIFIED POLYPEPTIDES, USED PRIMARILY AS HORMONES (HS CODE - 2937) 93
TABLE 20 TOP 10 EXPORTERS OF HORMONES, PROSTAGLANDINS, THROMBOXANES AND LEUKOTRIENES, NATURAL OR REPRODUCED BY SYNTHESIS; DERIVATIVES AND STRUCTURAL ANALOGUES THEREOF INCLUDE CHAIN-MODIFIED POLYPEPTIDES, USED PRIMARILY AS HORMONES (HS CODE - 2937) 93
6 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE 94
6.1 INTRODUCTION 95
TABLE 21 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 95
6.2 ACTIVE PHARMACEUTICAL INGREDIENTS, BY TYPE (CAPTIVE AND MERCHANT) 95
TABLE 22 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE (CAPTIVE AND MERCHANT), 2020-2027 (USD BILLION) 95
TABLE 23 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 96
6.3 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS 96
6.3.1 GROWING NUMBER OF NEW MOLECULAR ENTITIES GAINING REGULATORY APPROVALS TO DRIVE MARKET 96
TABLE 24 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2020-2027 (USD BILLION) 97
TABLE 25 NORTH AMERICA: INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 97
TABLE 26 EUROPE: INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 98
TABLE 27 ASIA PACIFIC: INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 98
TABLE 28 REST OF THE WORLD: INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 99
6.4 GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS 99
6.4.1 GOVERNMENT INITIATIVES SUPPORTING ADOPTION OF GENERIC DRUGS TO BOOST MARKET GROWTH 99
TABLE 29 GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2020-2027 (USD BILLION) 99
TABLE 30 NORTH AMERICA: GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 100
TABLE 31 EUROPE: GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 100
TABLE 32 ASIA PACIFIC: GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 101
TABLE 33 REST OF THE WORLD: GENERIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 101
7 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY 102
7.1 INTRODUCTION 103
TABLE 34 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION) 103
7.2 TRADITIONAL ACTIVE PHARMACEUTICAL INGREDIENTS 103
7.2.1 APPLICATION IN VARIOUS THERAPEUTIC AREAS TO SUPPORT MARKET GROWTH 103
TABLE 35 TRADITIONAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2020-2027 (USD BILLION) 104
TABLE 36 NORTH AMERICA: TRADITIONAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 104
TABLE 37 EUROPE: TRADITIONAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 104
TABLE 38 ASIA PACIFIC: TRADITIONAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 105
TABLE 39 REST OF THE WORLD: TRADITIONAL ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 105
7.3 HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENTS 105
7.3.1 INCREASING APPLICATION ACROSS RANGE OF THERAPEUTIC AREAS TO DRIVE MARKET 105
TABLE 40 HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2020-2027 (USD BILLION) 106
TABLE 41 NORTH AMERICA: HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 106
TABLE 42 EUROPE: HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 107
TABLE 43 ASIA PACIFIC: HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 107
TABLE 44 REST OF THE WORLD: HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 108
8 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS 109
8.1 INTRODUCTION 110
TABLE 45 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION) 110
?
8.2 ACTIVE PHARMACEUTICAL INGREDIENTS, BY TYPE OF SYNTHESIS
(CAPTIVE AND MERCHANT) 110
TABLE 46 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS (CAPTIVE AND MERCHANT), 2020-2027 (USD BILLION) 110
TABLE 47 CAPTIVE ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION) 111
8.3 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS 111
TABLE 48 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2020-2027 (USD BILLION) 112
TABLE 49 NORTH AMERICA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 112
TABLE 50 EUROPE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 113
TABLE 51 ASIA PACIFIC: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 113
TABLE 52 REST OF THE WORLD: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 114
8.3.1 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE 114
TABLE 53 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 114
8.3.1.1 Innovative synthetic APIs 115
8.3.1.1.1 High value of innovative APIs to drive market 115
TABLE 54 INNOVATIVE SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2020-2027 (USD BILLION) 115
TABLE 55 NORTH AMERICA: INNOVATIVE SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 115
TABLE 56 EUROPE: INNOVATIVE SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 116
TABLE 57 ASIA PACIFIC: INNOVATIVE SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 116
TABLE 58 REST OF THE WORLD: INNOVATIVE SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 117
8.3.1.2 Generic synthetic APIs 117
8.3.1.2.1 Initiatives to promote penetration of generics to support market growth 117
TABLE 59 GENERIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2020-2027 (USD BILLION) 118
TABLE 60 NORTH AMERICA: GENERIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 118
TABLE 61 EUROPE: GENERIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 119
TABLE 62 ASIA PACIFIC: GENERIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 119
TABLE 63 REST OF THE WORLD: GENERIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 120
8.4 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS 120
TABLE 64 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2020-2027 (USD BILLION) 121
TABLE 65 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 121
TABLE 66 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 122
TABLE 67 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 122
TABLE 68 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 123
8.4.1 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE 123
TABLE 69 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 123
8.4.1.1 Innovative biotech APIs 123
8.4.1.1.1 Growing demand for innovative biopharmaceuticals to drive market 123
TABLE 70 INNOVATIVE BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2020-2027 (USD BILLION) 124
TABLE 71 NORTH AMERICA: INNOVATIVE BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 124
TABLE 72 EUROPE: INNOVATIVE BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 125
TABLE 73 ASIA PACIFIC: INNOVATIVE BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 125
TABLE 74 REST OF THE WORLD: INNOVATIVE BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 126
8.4.1.2 Generic biotech APIs 126
8.4.1.2.1 Increasing demand for biosimilar drugs due to cost-effectiveness to drive market 126
TABLE 75 GENERIC BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2020-2027 (USD BILLION) 127
TABLE 76 NORTH AMERICA: GENERIC BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 127
TABLE 77 EUROPE: GENERIC BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 128
TABLE 78 ASIA PACIFIC: GENERIC BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 128
TABLE 79 REST OF THE WORLD: GENERIC BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 129
8.4.2 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT 129
TABLE 80 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION) 129
8.4.2.1 Monoclonal antibodies 130
8.4.2.1.1 Growing applications of antibody-drug conjugates in treatment of cancer to drive growth 130
TABLE 81 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2020-2027 (USD BILLION) 130
TABLE 82 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2020-2027 (USD BILLION) 131
TABLE 83 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2020-2027 (USD BILLION) 131
TABLE 84 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2020-2027 (USD BILLION) 132
TABLE 85 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2020-2027 (USD BILLION) 132
8.4.2.2 Hormones and growth factors 132
8.4.2.2.1 Growing incidence of hormonal disorders to drive market 132
TABLE 86 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES AND GROWTH FACTORS, BY REGION, 2020-2027 (USD BILLION) 133
TABLE 87 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES & GROWTH FACTORS, BY COUNTRY, 2020-2027 (USD BILLION) 133
TABLE 88 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES & GROWTH FACTORS, BY COUNTRY, 2020-2027 (USD BILLION) 134
TABLE 89 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES & GROWTH FACTORS, BY COUNTRY, 2020-2027 (USD BILLION) 134
TABLE 90 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR HORMONES & GROWTH FACTORS, BY COUNTRY, 2020-2027 (USD BILLION) 135
8.4.2.3 Cytokines 135
8.4.2.3.1 Interferons and interleukins boost immune system 135
TABLE 91 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY REGION, 2020-2027 (USD BILLION) 135
TABLE 92 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY COUNTRY, 2020-2027 (USD BILLION) 136
TABLE 93 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY COUNTRY, 2020-2027 (USD BILLION) 136
TABLE 94 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY COUNTRY, 2020-2027 (USD BILLION) 137
TABLE 95 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CYTOKINES, BY COUNTRY, 2020-2027 (USD BILLION) 137
8.4.2.4 Fusion proteins 137
8.4.2.4.1 Growing applications of fusion proteins in biopharmaceuticals to drive market 137
TABLE 96 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY REGION, 2020-2027 (USD BILLION) 138
TABLE 97 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2020-2027 (USD BILLION) 138
TABLE 98 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2020-2027 (USD BILLION) 139
TABLE 99 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2020-2027 (USD BILLION) 139
TABLE 100 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR FUSION PROTEINS, BY COUNTRY, 2020-2027 (USD BILLION) 140
8.4.2.5 Recombinant vaccines 140
8.4.2.5.1 Growing prevalence of infectious diseases to boost vaccine development 140
TABLE 101 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY REGION, 2020-2027 (USD BILLION) 140
TABLE 102 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2020-2027 (USD BILLION) 141
TABLE 103 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2020-2027 (USD BILLION) 141
TABLE 104 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2020-2027 (USD BILLION) 142
TABLE 105 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RECOMBINANT VACCINES, BY COUNTRY, 2020-2027 (USD BILLION) 142
8.4.2.6 Therapeutic enzymes 142
8.4.2.6.1 Growing significance of enzymes in therapies for cancer and pain management to drive market 142
TABLE 106 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY REGION, 2020-2027 (USD BILLION) 143
TABLE 107 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2020-2027 (USD BILLION) 143
TABLE 108 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2020-2027 (USD BILLION) 144
TABLE 109 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, BY COUNTRY, 2020-2027 (USD BILLION) 144
TABLE 110 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR THERAPEUTIC ENZYMES, 2020-2027 (USD BILLION) 145
8.4.2.7 Blood factors 145
8.4.2.7.1 Growing incidence of hemophilia to drive market 145
TABLE 111 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS, BY REGION, 2020-2027 (USD BILLION) 145
TABLE 112 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS, BY COUNTRY, 2020-2027 (USD BILLION) 146
TABLE 113 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS, BY COUNTRY, 2020-2027 (USD BILLION) 146
TABLE 114 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS, BY COUNTRY, 2020-2027 (USD BILLION) 147
TABLE 115 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR BLOOD FACTORS, 2020-2027 (USD BILLION) 147
8.4.3 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM 148
TABLE 116 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION) 148
8.4.3.1 Mammalian expression systems 148
8.4.3.1.1 Ability to carry post-translational modifications to drive adoption 148
TABLE 117 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY REGION, 2020-2027 (USD BILLION) 149
TABLE 118 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2020-2027 (USD BILLION) 149
TABLE 119 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2020-2027 (USD BILLION) 150
TABLE 120 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2020-2027 (USD BILLION) 150
TABLE 121 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MAMMALIAN EXPRESSION SYSTEMS, BY COUNTRY, 2020-2027 (USD BILLION) 151
8.4.3.2 Microbial expression systems 151
8.4.3.2.1 High expression levels of proteins at low costs to drive market 151
TABLE 122 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY REGION, 2020-2027 (USD BILLION) 151
TABLE 123 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2020-2027 (USD BILLION) 152
TABLE 124 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2020-2027 (USD BILLION) 152
TABLE 125 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2020-2027 (USD BILLION) 153
TABLE 126 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR MICROBIAL EXPRESSION SYSTEMS, BY COUNTRY, 2020-2027 (USD BILLION) 153
8.4.3.3 Yeast expression systems 153
8.4.3.3.1 Efficient protein secretion, simple purification, and endotoxin-free products to boost demand 153
TABLE 127 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY REGION, 2020-2027 (USD BILLION) 154
TABLE 128 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2020-2027 (USD BILLION) 154
TABLE 129 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2020-2027 (USD BILLION) 155
TABLE 130 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2020-2027 (USD BILLION) 155
TABLE 131 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR YEAST EXPRESSION SYSTEMS, BY COUNTRY, 2020-2027 (USD BILLION) 156
8.4.3.4 Insect expression systems 156
8.4.3.4.1 Efficient post-translational modifications to boost adoption 156
TABLE 132 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY REGION, 2020-2027 (USD BILLION) 156
TABLE 133 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2020-2027 (USD BILLION) 157
TABLE 134 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2020-2027 (USD BILLION) 157
TABLE 135 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2020-2027 (USD BILLION) 158
TABLE 136 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR INSECT EXPRESSION SYSTEMS, BY COUNTRY, 2020-2027 (USD BILLION) 158
8.4.3.5 Other expression systems 158
TABLE 137 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY REGION, 2020-2027 (USD BILLION) 159
TABLE 138 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY COUNTRY, 2020-2027 (USD BILLION) 159
TABLE 139 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY COUNTRY, 2020-2027 (USD BILLION) 160
TABLE 140 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY COUNTRY, 2020-2027 (USD BILLION) 160
TABLE 141 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER EXPRESSION SYSTEMS, BY COUNTRY, 2020-2027 (USD BILLION) 161
9 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG 162
9.1 INTRODUCTION 163
TABLE 142 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION) 163
9.2 PRESCRIPTION DRUGS 163
9.2.1 GROWING DISEASE PREVALENCE TO SUPPORT MARKET GROWTH 163
TABLE 143 PRESCRIPTION DRUGS MARKET, BY REGION, 2020-2027 (USD BILLION) 164
TABLE 144 NORTH AMERICA: PRESCRIPTION DRUGS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 164
TABLE 145 EUROPE: PRESCRIPTION DRUGS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 165
TABLE 146 ASIA PACIFIC: PRESCRIPTION DRUGS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 165
TABLE 147 REST OF THE WORLD: PRESCRIPTION DRUGS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 166
9.3 OVER-THE-COUNTER DRUGS 166
9.3.1 INCREASED SALES OF OTC DRUGS DUE TO INNOVATIONS, PROMOTION OF SELF-MEDICATION, AND INCREASED ACCESS 166
TABLE 148 OVER-THE-COUNTER DRUGS MARKET, BY REGION, 2020-2027 (USD BILLION) 167
TABLE 149 NORTH AMERICA: OVER-THE-COUNTER DRUGS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 167
TABLE 150 EUROPE: OVER-THE-COUNTER DRUGS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 168
TABLE 151 ASIA PACIFIC: OVER-THE-COUNTER DRUGS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 168
TABLE 152 REST OF THE WORLD: OVER-THE-COUNTER DRUGS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 169
10 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET,
BY THERAPEUTIC APPLICATION 170
10.1 INTRODUCTION 171
TABLE 153 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION) 171
10.2 COMMUNICABLE DISEASES 171
10.2.1 LARGEST AND FASTEST-GROWING MARKET SEGMENT 171
TABLE 154 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY REGION, 2020-2027 (USD BILLION) 172
TABLE 155 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2020-2027 (USD BILLION) 172
TABLE 156 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2020-2027 (USD BILLION) 173
TABLE 157 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2020-2027 (USD BILLION) 173
TABLE 158 REST OF THE WORLD: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR COMMUNICABLE DISEASES, BY COUNTRY, 2020-2027 (USD BILLION) 174
10.3 ONCOLOGY 174
10.3.1 INCREASING SPENDING ON CANCER MEDICATION TO SUPPORT MARKET GROWTH 174
TABLE 159 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY REGION, 2020-2027 (USD BILLION) 174
TABLE 160 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2020-2027 (USD BILLION) 175
TABLE 161 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2020-2027 (USD BILLION) 175
TABLE 162 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2020-2027 (USD BILLION) 176
TABLE 163 REST OF THE WORLD: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR ONCOLOGY, BY COUNTRY, 2020-2027 (USD BILLION) 176
10.4 DIABETES 177
10.4.1 HIGH PREVALENCE OF DIABETES TO DRIVE MARKET 177
TABLE 164 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY REGION, 2020-2027 (USD BILLION) 177
TABLE 165 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2020-2027 (USD BILLION) 177
TABLE 166 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2020-2027 (USD BILLION) 178
TABLE 167 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2020-2027 (USD BILLION) 178
TABLE 168 REST OF THE WORLD: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR DIABETES, BY COUNTRY, 2020-2027 (USD BILLION) 179
10.5 CARDIOVASCULAR DISEASES 179
10.5.1 GROWING INCIDENCE OF CARDIOVASCULAR DISEASES OWING TO SEDENTARY LIFESTYLES 179
TABLE 169 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2020-2027 (USD BILLION) 179
TABLE 170 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020-2027 (USD BILLION) 180
TABLE 171 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020-2027 (USD BILLION) 180
TABLE 172 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020-2027 (USD BILLION) 181
TABLE 173 REST OF THE WORLD: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2020-2027 (USD BILLION) 181
10.6 PAIN MANAGEMENT 182
10.6.1 INCREASING DEMAND FOR INNOVATIVE AND ADVANCED PAIN MEDICATIONS TO PROPEL MARKET 182
TABLE 174 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY REGION, 2020-2027 (USD BILLION) 182
TABLE 175 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2020-2027 (USD BILLION) 182
TABLE 176 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2020-2027 (USD BILLION) 183
TABLE 177 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2020-2027 (USD BILLION) 183
TABLE 178 REST OF THE WORLD: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2020-2027 (USD BILLION) 184
10.7 RESPIRATORY DISEASES 184
10.7.1 HIGH PREVALENCE OF RESPIRATORY DISEASES TO SUPPORT MARKET GROWTH 184
TABLE 179 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY REGION, 2020-2027 (USD BILLION) 184
TABLE 180 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2020-2027 (USD BILLION) 185
TABLE 181 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2020-2027 (USD BILLION) 185
TABLE 182 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2020-2027 (USD BILLION) 186
TABLE 183 REST OF THE WORLD: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2020-2027 (USD BILLION) 186
10.8 OTHER THERAPEUTIC APPLICATIONS 186
TABLE 184 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY REGION, 2020-2027 (USD BILLION) 187
TABLE 185 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD BILLION) 187
TABLE 186 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD BILLION) 188
TABLE 187 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD BILLION) 188
TABLE 188 REST OF THE WORLD: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020-2027 (USD BILLION) 189

11 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION 190
11.1 INTRODUCTION 191
TABLE 189 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY REGION, 2020-2027 (USD BILLION) 191
11.2 NORTH AMERICA 191
FIGURE 23 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT 192
TABLE 190 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 193
TABLE 191 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 193
TABLE 192 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 USD BILLION) 193
TABLE 193 NORTH AMERICA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 194
TABLE 194 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 194
TABLE 195 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION) 194
TABLE 196 NORTH AMERICA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION) 195
TABLE 197 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION) 195
TABLE 198 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION) 195
TABLE 199 NORTH AMERICA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION) 196
11.2.1 US 196
11.2.1.1 Largest market for active pharmaceutical ingredients 196
TABLE 200 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 197
TABLE 201 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION) 197
TABLE 202 US: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 197
TABLE 203 US: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 198
TABLE 204 US: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION) 198
TABLE 205 US: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION) 199
TABLE 206 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION) 199
TABLE 207 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION) 199
TABLE 208 US: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION) 200
?
11.2.2 CANADA 200
11.2.2.1 Growing pharmaceutical manufacturing to support market growth 200
TABLE 209 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 201
TABLE 210 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION) 201
TABLE 211 CANADA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 201
TABLE 212 CANADA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 202
TABLE 213 CANADA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION) 202
TABLE 214 CANADA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION) 203
TABLE 215 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION) 203
TABLE 216 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION) 203
TABLE 217 CANADA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION) 204
11.3 EUROPE 204
TABLE 218 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 205
TABLE 219 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 205
TABLE 220 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION) 205
TABLE 221 EUROPE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 206
TABLE 222 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 206
TABLE 223 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION) 207
TABLE 224 EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION) 207
TABLE 225 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION) 208
TABLE 226 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION) 208
TABLE 227 EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION) 208
11.3.1 GERMANY 209
11.3.1.1 Leading country in terms of infrastructure and competency for R&D 209
TABLE 228 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 209
TABLE 229 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION) 210
TABLE 230 GERMANY: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 210
TABLE 231 GERMANY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 210
TABLE 232 GERMANY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION) 211
TABLE 233 GERMANY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION) 211
TABLE 234 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION) 212
TABLE 235 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION) 212
TABLE 236 GERMANY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION) 212
11.3.2 FRANCE 213
11.3.2.1 Healthy pharmaceutical production to support API demand 213
TABLE 237 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 213
TABLE 238 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION) 213
TABLE 239 FRANCE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 214
TABLE 240 FRANCE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 214
TABLE 241 FRANCE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION) 215
TABLE 242 FRANCE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION) 215
TABLE 243 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION) 216
TABLE 244 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION) 216
TABLE 245 FRANCE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION) 216
11.3.3 UK 217
11.3.3.1 Rising government investments to drive market 217
TABLE 246 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 217
TABLE 247 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION) 217
TABLE 248 UK: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 218
TABLE 249 UK: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 218
TABLE 250 UK: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION) 219
TABLE 251 UK: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION) 219
TABLE 252 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION) 220
TABLE 253 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION) 220
TABLE 254 UK: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION) 221
11.3.4 ITALY 221
11.3.4.1 Growing investment in API production to support market growth 221
TABLE 255 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 222
TABLE 256 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION) 222
TABLE 257 ITALY: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 222
TABLE 258 ITALY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 223
TABLE 259 ITALY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION) 223
TABLE 260 ITALY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION) 224
TABLE 261 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION) 224
TABLE 262 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION) 224
TABLE 263 ITALY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION) 225
11.3.5 SPAIN 225
11.3.5.1 Increase in generic drug manufacturing capacity to propel demand for APIs 225
TABLE 264 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 226
TABLE 265 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION) 226
TABLE 266 SPAIN: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 226
TABLE 267 SPAIN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 227
TABLE 268 SPAIN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION) 227
TABLE 269 SPAIN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION) 228
TABLE 270 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION) 228
TABLE 271 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION) 228
TABLE 272 SPAIN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION) 229
11.3.6 HUNGARY 229
11.3.6.1 Rising incidence of chronic diseases to propel market growth 229
TABLE 273 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 229
TABLE 274 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION) 230
TABLE 275 HUNGARY: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 230
TABLE 276 HUNGARY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 230
TABLE 277 HUNGARY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION) 231
TABLE 278 HUNGARY: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION) 231
TABLE 279 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION) 232
TABLE 280 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION) 232
TABLE 281 HUNGARY: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION) 233
11.3.7 REST OF EUROPE 233
TABLE 282 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 233
TABLE 283 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION) 234
TABLE 284 REST OF EUROPE: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 234
TABLE 285 REST OF EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 234
TABLE 286 REST OF EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION) 235
TABLE 287 REST OF EUROPE: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION) 235
TABLE 288 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION) 236
TABLE 289 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION) 236
TABLE 290 REST OF EUROPE: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION) 237
11.4 ASIA PACIFIC 237
FIGURE 24 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SNAPSHOT 238
TABLE 291 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 239
TABLE 292 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 239
TABLE 293 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION) 239
TABLE 294 ASIA PACIFIC: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 240
TABLE 295 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 240
TABLE 296 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION) 241
TABLE 297 ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION) 241
TABLE 298 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION) 242
TABLE 299 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION) 242
TABLE 300 ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION) 243
11.4.1 JAPAN 243
11.4.1.1 Presence of large pharmaceutical companies to propel market 243
TABLE 301 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 244
TABLE 302 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION) 244
TABLE 303 JAPAN: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 244
TABLE 304 JAPAN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 245
TABLE 305 JAPAN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION) 245
TABLE 306 JAPAN: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION) 246
TABLE 307 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION) 246
TABLE 308 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION) 246
TABLE 309 JAPAN: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION) 247
11.4.2 CHINA 247
11.4.2.1 Government policies to increase medicine access and affordability to support market growth 247
TABLE 310 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 248
TABLE 311 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION) 248
TABLE 312 CHINA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 248
TABLE 313 CHINA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 249
TABLE 314 CHINA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION) 249
TABLE 315 CHINA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION) 250
TABLE 316 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION) 250
TABLE 317 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION) 250
TABLE 318 CHINA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION) 251
11.4.3 INDIA 251
11.4.3.1 Leading producer of generics 251
TABLE 319 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 252
TABLE 320 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION) 252
TABLE 321 INDIA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 252
TABLE 322 INDIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 253
TABLE 323 INDIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION) 253
TABLE 324 INDIA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION) 254
TABLE 325 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION) 254
TABLE 326 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION) 254
TABLE 327 INDIA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION) 255
11.4.4 SOUTH KOREA 255
11.4.4.1 Rising annual drug exports to drive market 255
TABLE 328 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 256
TABLE 329 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION) 256
TABLE 330 SOUTH KOREA: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 256
TABLE 331 SOUTH KOREA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 257
TABLE 332 SOUTH KOREA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION) 257
TABLE 333 SOUTH KOREA: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION) 258
TABLE 334 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION) 258
TABLE 335 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION) 258
TABLE 336 SOUTH KOREA: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION) 259
11.4.5 REST OF ASIA PACIFIC 259
TABLE 337 REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 259
TABLE 338 REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION) 260
TABLE 339 REST OF ASIA PACIFIC: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 260
TABLE 340 REST OF ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 260
TABLE 341 REST OF ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION) 261
TABLE 342 REST OF ASIA PACIFIC: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION) 261
TABLE 343 REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION) 262
TABLE 344 REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION) 262
TABLE 345 REST OF ASIA PACIFIC: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION) 263
11.5 REST OF THE WORLD 263
TABLE 346 REST OF THE WORLD: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY COUNTRY, 2020-2027 (USD BILLION) 263
TABLE 347 REST OF THE WORLD: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 264
TABLE 348 REST OF THE WORLD: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION) 264
TABLE 349 REST OF THE WORLD: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 264
TABLE 350 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 265
TABLE 351 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION) 265
TABLE 352 REST OF THE WORLD: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION) 266
TABLE 353 REST OF THE WORLD: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION) 266
TABLE 354 REST OF THE WORLD: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION) 266
TABLE 355 REST OF THE WORLD: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION) 267
11.5.1 ISRAEL 267
11.5.1.1 Financial support by government to drive market 267
TABLE 356 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 267
TABLE 357 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION) 268
TABLE 358 ISRAEL: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 268
TABLE 359 ISRAEL: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 268
TABLE 360 ISRAEL: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION) 269
TABLE 361 ISRAEL: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION) 269
TABLE 362 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION) 270
TABLE 363 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION) 270
TABLE 364 ISRAEL: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION) 271
11.5.2 OTHER COUNTRIES 271
TABLE 365 OTHER COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 271
TABLE 366 OTHER COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF SYNTHESIS, 2020-2027 (USD BILLION) 272
TABLE 367 OTHER COUNTRIES: SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 272
TABLE 368 OTHER COUNTRIES: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE, 2020-2027 (USD BILLION) 272
TABLE 369 OTHER COUNTRIES: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY PRODUCT, 2020-2027 (USD BILLION) 273
TABLE 370 OTHER COUNTRIES: BIOTECH ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY EXPRESSION SYSTEM, 2020-2027 (USD BILLION) 273
TABLE 371 OTHER COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY TYPE OF DRUG, 2020-2027 (USD BILLION) 274
TABLE 372 OTHER COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY POTENCY, 2020-2027 (USD BILLION) 274
TABLE 373 OTHER COUNTRIES: ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, BY THERAPEUTIC APPLICATION, 2020-2027 (USD BILLION) 275
12 COMPETITIVE LANDSCAPE 276
12.1 OVERVIEW 276
12.2 STRATEGIES ADOPTED BY KEY PLAYERS 277
FIGURE 25 KEY DEVELOPMENTS IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, 2019-2022 277
12.3 MARKET SHARE ANALYSIS 278
FIGURE 26 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2021 278
TABLE 374 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: DEGREE OF COMPETITION 278
12.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 280
FIGURE 27 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET, 2019-2021 280
12.5 COMPANY EVALUATION QUADRANT 281
12.5.1 STARS 281
12.5.2 EMERGING LEADERS 281
12.5.3 PERVASIVE PLAYERS 281
12.5.4 PARTICIPANTS 281
FIGURE 28 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: COMPANY EVALUATION QUADRANT, 2021 282
12.6 COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES 283
12.6.1 PROGRESSIVE COMPANIES 283
12.6.2 STARTING BLOCKS 283
12.6.3 RESPONSIVE COMPANIES 283
12.6.4 DYNAMIC COMPANIES 283
FIGURE 29 ACTIVE PHARMACEUTICAL INGREDIENTS MARKET: COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES, 2021 284
12.7 REGIONAL FOOTPRINT OF COMPANIES 285
TABLE 375 REGIONAL FOOTPRINT OF COMPANIES IN ACTIVE PHARMACEUTICAL INGREDIENTS MARKET (2021) 285
12.8 COMPETITIVE SCENARIO 286
TABLE 376 KEY PRODUCT LAUNCHES 286
TABLE 377 KEY DEALS 286
TABLE 378 OTHER KEY DEVELOPMENTS 287
13 COMPANY PROFILES 288
13.1 KEY PLAYERS 288
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
13.1.1 PFIZER INC. 288
TABLE 379 PFIZER INC.: COMPANY OVERVIEW 288
FIGURE 30 PFIZER, INC.: COMPANY SNAPSHOT (2021) 289
13.1.2 TEVA PHARMACEUTICAL INDUSTRIES LTD. 294
TABLE 380 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW 294
FIGURE 31 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2021) 294
13.1.3 DIVIS LABORATORIES LIMITED 297
TABLE 381 DIVIS LABORATORIES LIMITED: COMPANY OVERVIEW 297
FIGURE 32 DIVIS LABORATORIES LIMITED: COMPANY SNAPSHOT (2021) 297
13.1.4 VIATRIS INC. 300
TABLE 382 VIATRIS INC.: COMPANY OVERVIEW 300
FIGURE 33 VIATRIS INC.: COMPANY SNAPSHOT (2021) 301
13.1.5 NOVARTIS AG 304
TABLE 383 NOVARTIS AG: COMPANY OVERVIEW 304
FIGURE 34 NOVARTIS AG: COMPANY SNAPSHOT (2021) 305
13.1.6 SANOFI 309
TABLE 384 SANOFI: COMPANY OVERVIEW 309
FIGURE 35 SANOFI: COMPANY SNAPSHOT (2021) 310
13.1.7 BOEHRINGER INGELHEIM 313
TABLE 385 BOEHRINGER INGELHEIM: COMPANY OVERVIEW 313
FIGURE 36 BOEHRINGER INGELHEIM: COMPANY SNAPSHOT (2021) 314
13.1.8 BRISTOL-MYERS SQUIBB 318
TABLE 386 BRISTOL-MYERS SQUIBB: COMPANY OVERVIEW 318
FIGURE 37 BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT (2021) 319
13.1.9 ELI LILLY AND COMPANY 322
TABLE 387 ELI LILLY AND COMPANY: COMPANY OVERVIEW 322
FIGURE 38 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2021) 323
13.1.10 GLAXOSMITHKLINE PLC 326
TABLE 388 GLAXOSMITHKLINE PLC: COMPANY OVERVIEW 326
FIGURE 39 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT (2021) 327
13.1.11 MERCK & CO., INC. 331
TABLE 389 MERCK & CO., INC.: COMPANY OVERVIEW 331
FIGURE 40 MERCK & CO., INC.: COMPANY SNAPSHOT (2021) 332
13.1.12 ABBVIE INC. 335
TABLE 390 ABBVIE INC.: COMPANY OVERVIEW 335
FIGURE 41 ABBVIE INC.: COMPANY SNAPSHOT (2021) 336
13.1.13 F. HOFFMANN-LA ROCHE LTD. 339
TABLE 391 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 339
FIGURE 42 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2021) 340
13.1.14 ASTRAZENECA 342
TABLE 392 ASTRAZENECA: COMPANY OVERVIEW 342
FIGURE 43 ASTRAZENECA: COMPANY SNAPSHOT (2021) 342
13.1.15 DR. REDDYS LABORATORIES LTD. 346
TABLE 393 DR. REDDYS LABORATORIES LTD.: COMPANY OVERVIEW 346
FIGURE 44 DR. REDDYS LABORATORIES LTD.: COMPANY SNAPSHOT (2021) 347
13.1.16 SUN PHARMACEUTICAL INDUSTRIES LTD. 352
TABLE 394 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW 352
FIGURE 45 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2021) 353
13.1.17 CIPLA INC. 357
TABLE 395 CIPLA INC.: COMPANY OVERVIEW 357
FIGURE 46 CIPLA INC.: COMPANY SNAPSHOT (2021) 358
13.1.18 AUROBINDO PHARMA 362
TABLE 396 AUROBINDO PHARMA: COMPANY OVERVIEW 362
FIGURE 47 AUROBINDO PHARMA LTD.: COMPANY SNAPSHOT (2021) 363
13.1.19 EVONIK INDUSTRIES AG 365
TABLE 397 EVONIK INDUSTRIES AG: COMPANY OVERVIEW 365
FIGURE 48 EVONIK INDUSTRIES AG: COMPANY SNAPSHOT (2021) 366
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
13.2 OTHER PLAYERS 368
13.2.1 API PHARMA TECH 368
13.2.2 BDR PHARMACEUTICALS INTERNATIONALS PVT. LTD. 368
13.2.3 SREEPATHI PHARMACEUTICALS LIMITED 369
13.2.4 SHILPA MEDICARE LIMITED 369
14 APPENDIX 370
14.1 DISCUSSION GUIDE 370
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS SUBSCRIPTION PORTAL 374
14.3 CUSTOMIZATION OPTIONS 376
14.4 RELATED REPORTS 376
14.5 AUTHOR DETAILS 377

  • Not Sure / Need Reassuring
    • Confirm Content
      • Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:

        Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.

        Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.

        Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.

    • Sample Pages
      • With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.

        It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.

        To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Check for Alternatives
      • Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.

        To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.

  • Prices / Formats / Delivery
    • Prices
      • All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.

        Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Discounts
      • As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.

        Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.

        To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Available Currencies
      • Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.

        Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.

        To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.

    • Licenses
      • License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Global Site License
      • The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.

        It is important to note that this may exclude Parent Companies or Subsidiaries.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Formats
      • The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.

        If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.

    • Delivery
      • Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.

        Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.

        If a delay in delivery is expected you will be informed about it immediately.

    • Shipping Charges
      • As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.

        If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.

  • Ordering
    • By Credit Card
      • We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.

        Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.

        For more information on PayU please visit: https://www.payu.pl/en/about-us

    • By Money Transfer
      • If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.

        With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.

  • Security
    • Website security
      • We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.

        Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.

    • Credit Card Security
      • We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.

        PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.

PLEASE SELECT LICENSE
  • $4950.00
  • $6650.00
  • $8150.00
  • $10000.00
  • ADD TO BASKET
  • BUY NOW